Positive Recommendation by IDMC Announced: ELI-002 7P Ph 2 Study in Pancreatic Cancer to Continue Without Modifications to Final Analysis August 12, 2025
FAILED TRIAL: Clinical but not significant PFS Improvement seen in Ph 3 Trial of Cylembio® plus KEYTRUDA® in 1L Advanced Melanoma August 12, 2025
First Patient Dosed in Ph 3 Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy August 12, 2025
Ph 3 EPCORE® FL-1 Trial Met Dual Primary Endpoints in Patients with R/R Follicular Lymphoma August 12, 2025
FDA Accepts NDA for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer August 12, 2025
U.S. FDA grants accelerated approval to HERNEXEOS® for previously treated patients with HER2-mutant advanced NSCLC August 12, 2025
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes August 12, 2025
Strand Therapeutics Raises $153M Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline August 12, 2025
NeOnc Technologies Awarded $2.5M in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia in Ph 2 trials August 12, 2025
First Patient Dosed in Ph 1 Trial of ATV-1601 in Patients with AKT1 E17K-mutant Solid Tumors August 12, 2025
Ph 1b trial of elraglusib, retifanlimab, and mFOLFIRINOX combo as 1L therapy in advanced pancreatic adenocarcinoma initiated August 12, 2025
Enrollment Open for 160 mg Dosing Cohort of Tuspetinib in Ph 1/2 TUSCANY Trial of 1L Triple Drug Therapy in induction-ineligible AML patients August 12, 2025
RP2D in Ph 1 Study of SENTI-202 for the Treatment of R/R Heme Malignancies, Including AML, Determined August 12, 2025
Mid-year report of Ampligen® (rintatolimod) & Imfinzi® combo in pancreatic cancer demonstrates no significant toxicity and superior PFS and OS August 12, 2025
24-Month DOR of 72.2% Announced from Ph 3 ENVISION Trial of ZUSDURI in Recurrent Low-Grade Intermediate-Risk NMIBC August 12, 2025
